Cell and gene therapies gain streamlined fda oversight

被引:0
|
作者
Wechsler, Jill
机构
来源
Pharmaceutical Technology | 2019年 / 43卷 / 03期
关键词
D O I
暂无
中图分类号
学科分类号
摘要
2
引用
收藏
页码:8 / 9
相关论文
共 50 条
  • [21] FDA pharmaceutical quality oversight
    Yu, Lawrence X.
    Woodcock, Janet
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 491 (1-2) : 2 - 7
  • [22] FDA tightens human oversight
    Dove, A
    NATURE MEDICINE, 2001, 7 (06) : 646 - 646
  • [23] FDA tightens human oversight
    Alan Dove
    Nature Medicine, 2001, 7 : 646 - 646
  • [24] FDA approval of Casgevy and Lyfgenia: a dual breakthrough in gene therapies for sickle cell disease
    Rahmat, Zainab Syyeda
    Ali, Mohammad Haris
    Talha, Muhammad
    Al Hasibuzzaman, Md
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (09): : 4966 - 4968
  • [25] A Review of the Cost-Effectiveness Evidence for FDA-Approved Cell and Gene Therapies
    Abuloha, Sumaya
    Niu, Shu
    Adirika, Darlene
    Harvey, Benjamin P.
    Svensson, Mikael
    HUMAN GENE THERAPY, 2024, 35 (11-12) : 365 - 373
  • [26] Streamlined collaboration can boost CRISPR gene therapies for rare diseases
    He, Wei
    Zeng, Shuxiong
    Xu, Chuanliang
    NATURE, 2024, 631 (8019) : 28 - 28
  • [28] FDA scrutinizes human stem cell therapies
    Jeffrey L Fox
    Nature Biotechnology, 2008, 26 : 598 - 599
  • [29] FDA scrutinizes human stem cell therapies
    Fox, Jeffrey L.
    NATURE BIOTECHNOLOGY, 2008, 26 (06) : 598 - 599
  • [30] FDA Proposes Streamlined Medication Handouts
    Wechsler, Jill
    BIOPHARM INTERNATIONAL, 2023, 36 (07)